Placing more resources toward and greater attention on its product Liprostin for peripheral arterial occlusive disease, Endovasc Inc. decided to stop funding preclinical research of a nicotine receptor agonist (NRA) in coronary artery disease. (BioWorld Today)

Encysive Pharmaceuticals Inc. set its lead drug candidate, Thelin (sitaxsentan), on the pathway toward approval for pulmonary arterial hypertension by filing a new drug application with the FDA. (BioWorld Today)